Updated results from an open-label phase 1/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma

Nathalie A. Johnson; David Lavie; Peter Borchmann; Gareth P. Gregory; Alex F. Herrera; Leonard Minuk; Vladan Vucinic; Philippe Armand; Abraham Avigdor; Robin Gasiorowski; Yair Herishanu; Colm Keane; John Kuruvilla; John Palcza; Pallavi Pillai; Akash Nahar; John Timmerman

doi:10.1182/blood-2022-166846

Updated results from an open-label phase 1/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	6540-6542
Number of pages	3
Journal	Blood
Volume	140
Issue number	Supplement 1
DOIs	https://doi.org/10.1182/blood-2022-166846
Publication status	Published - 15 Nov 2022
Externally published	Yes
Event	64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - New Orleans, United States Duration: 10 Dec 2022 → 13 Dec 2022

Access to Document

10.1182/blood-2022-166846

Cite this

Johnson, N. A., Lavie, D., Borchmann, P., Gregory, G. P., Herrera, A. F., Minuk, L., Vucinic, V., Armand, P., Avigdor, A., Gasiorowski, R., Herishanu, Y., Keane, C., Kuruvilla, J., Palcza, J., Pillai, P., Nahar, A., & Timmerman, J. (2022). Updated results from an open-label phase 1/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma. Blood, 140(Supplement 1), 6540-6542. https://doi.org/10.1182/blood-2022-166846

@article{9d7c93578e5d4e9aa84ff8c6c5ba3a50,

title = "Updated results from an open-label phase 1/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma",

author = "Johnson, {Nathalie A.} and David Lavie and Peter Borchmann and Gregory, {Gareth P.} and Herrera, {Alex F.} and Leonard Minuk and Vladan Vucinic and Philippe Armand and Abraham Avigdor and Robin Gasiorowski and Yair Herishanu and Colm Keane and John Kuruvilla and John Palcza and Pallavi Pillai and Akash Nahar and John Timmerman",

year = "2022",

month = nov,

day = "15",

doi = "10.1182/blood-2022-166846",

language = "English",

volume = "140",

pages = "6540--6542",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "Supplement 1",

note = "64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) ; Conference date: 10-12-2022 Through 13-12-2022",

}

Johnson, NA, Lavie, D, Borchmann, P, Gregory, GP, Herrera, AF, Minuk, L, Vucinic, V, Armand, P, Avigdor, A, Gasiorowski, R, Herishanu, Y, Keane, C, Kuruvilla, J, Palcza, J, Pillai, P, Nahar, A & Timmerman, J 2022, 'Updated results from an open-label phase 1/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma', Blood, vol. 140, no. Supplement 1, pp. 6540-6542. https://doi.org/10.1182/blood-2022-166846

TY - JOUR

T1 - Updated results from an open-label phase 1/2 study of favezelimab (anti-LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma

AU - Johnson, Nathalie A.

AU - Lavie, David

AU - Borchmann, Peter

AU - Gregory, Gareth P.

AU - Herrera, Alex F.

AU - Minuk, Leonard

AU - Vucinic, Vladan

AU - Armand, Philippe

AU - Avigdor, Abraham

AU - Gasiorowski, Robin

AU - Herishanu, Yair

AU - Keane, Colm

AU - Kuruvilla, John

AU - Palcza, John

AU - Pillai, Pallavi

AU - Nahar, Akash

AU - Timmerman, John

PY - 2022/11/15

Y1 - 2022/11/15

U2 - 10.1182/blood-2022-166846

DO - 10.1182/blood-2022-166846

M3 - Meeting abstract

SN - 0006-4971

VL - 140

SP - 6540

EP - 6542

JO - Blood

JF - Blood

IS - Supplement 1

T2 - 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Y2 - 10 December 2022 through 13 December 2022

ER -